Drug interactions
Duvelisib + Liposomal doxorubicin
Severity: Minor
Duvelisib and Liposomal doxorubicin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Duvelisib inhibits CYP3A4 and raises exposure to sensitive CYP3A4 substrates. Doxorubicin is only a minor CYP3A4 substrate, and the liposomal form is cleared mainly by other routes, so the effect is probably small. Both agents can cause myelosuppression and infection risk, so overlapping toxicity is the more practical concern.
What this interaction means in plain words
Duvelisib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Duvelisib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.
Why it happens
Duvelisib inhibits CYP3A4, a minor pathway for doxorubicin metabolism.
What to do
Monitor blood counts and for infections and cardiac toxicity during co-administration. Reduce the dose only if toxicity develops.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Duvelisib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Duvelisib
- Duvelisib + Ergotamine Contraindicated
- Alfuzosin + Duvelisib Major
- Apalutamide + Duvelisib Major
- Avanafil + Duvelisib Major
- Carbamazepine + Duvelisib Major
- Chloramphenicol + Duvelisib Major
Frequently asked questions
Can I take Duvelisib with Liposomal doxorubicin?
MediHelp rates the interaction as minor. Duvelisib and Liposomal doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Duvelisib inhibits CYP3A4 and raises exposure to sensitive CYP3A4 substrates. Doxorubicin is only a minor CYP3A4 substrate, and the liposomal form is cleared mainly by other routes, so the effect is probably small. Both agents can cause myelosuppression and infection risk, so overlapping toxicity is the more practical concern.
How serious is the interaction between Duvelisib and Liposomal doxorubicin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and for infections and cardiac toxicity during co-administration. Reduce the dose only if toxicity develops.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
